| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/06/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Unicycive Therapeutics, Inc. |
| 07/06/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in UNICYCIVE THERAPEUTICS, INC. |
| 06/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/23/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/16/2023 |
8-K
| Quarterly results |
| 05/16/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/16/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/31/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/30/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 03/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock",
"Form of Specimen Stock Certificate for Series A-1 Preferred Stock",
"Form of Tranche A Warrant",
"Form of Tranche B Warrant",
"Form of Tranche C Warrant",
"Form of Securities Purchase Agreement, by and between Unicycive Therapeutics, Inc. and the purchasers named therein",
"Placement Agency Agreement, by and between Unicycive Therapeutics, Inc. and EF Hutton, division of Benchmark Investments, LLC",
"Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb" |
|
| 03/02/2023 |
8-K
| Other Events Interactive Data |
| 02/14/2023 |
SC 13G/A
| Nantahala Capital Management, LLC reports a 8% stake in UNICYCIVE THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 6.1% stake in UNICYCIVE THERAPEUTICS, INC. |
| 02/07/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 02/02/2023 |
8-K
| Quarterly results |
| 12/29/2022 |
8-K
| Quarterly results |
| 12/28/2022 |
8-K
| Investor presentation |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/25/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/15/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 07/18/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
|